ABSTRACT: For >4 decades, the holy grail in the treatment of acute myocardial infarction has been the mitigation of lethal injury. Despite promising initial results and decades of investigation by the cardiology research community, the only treatment with proven efficacy is early reperfusion of the occluded coronary artery. The remarkable record of failure has led us and others to wonder if cardioprotection is dead. The path to translation, like the ascent to Everest, is certainly littered with corpses. We do, however, highlight a therapeutic principle that provides a glimmer of hope: cellular postconditioning. Administration of cardiosphere-derived cells after reperfusion limits infarct size measured acutely, while providing long-term structural and functional benefits. The recognition that cell therapy may be cardioprotective, and not just regenerative, merits further exploration before we abandon the pursuit entirely.
tional Heart, Lung, and Blood Institute established a network called the Consortium for Preclinical Assessment of Cardioprotective Therapies (CAESAR) that was based on the principles of clinical trials (ie, randomization, investigator blinding, exclusion criteria, and appropriate statistical analyses). A number of putatively cardioprotective agents were tested in the CAESAR network, but none was found to be effective under these rigorous experimental conditions. Table 1 summarizes failures to confirm once-promising preclinical data, including those debunked by CAESAR and publicly reported (many others failed in CAESAR but results have not yet been published). Independent of CAESAR, a number of drugs have been tested in patients, with similarly dispiriting results ( Table 2 ). In particular, once the tissue has been reperfused, nothing seems to work. Patients can rarely predict when they will have an AMI, and doctors similarly lack clairvoyance. Ischemic postconditioning (created by cyclic intracoronary balloon inflations) requires immediate manipulation of flow at the time of reperfusion, with loss of benefit if there is delay. 29, 30 A key consideration of any adjunctive therapy is compatibility with standard clinical practice: in assessing new therapies, it is important to devise interventions that work even after the occluded artery has been successfully opened.
Despite the disappointments to date, a new direction has arisen from an unlikely corner: cell therapy. The conventional rationale for cell therapy is to trigger regeneration, not cardioprotection. The dogma is as follows: progenitor cells, if transplanted into the postischemic heart, will implant, proliferate, and differentiate into vi- 
CELL THERAPY FOR AMI
Numerous lines of evidence now support the idea that cells can either be cardioprotective (when administered during or soon after AMI) or regenerative (when administered after scar is well established). Work in a bitransgenic fate-mapping mouse model revealed that the 2 mechanisms are not mutually exclusive: they contribute roughly equally to the long-term (3 weeks post-MI) increase in myocardial viability when cells are given shortly after permanent coronary ligation. 31 Three-week end points or longer will lump both contributions together; short-term end points (eg, 48 hours) enable study of the cardioprotective effect in isolation, well before the regenerative mechanisms of cardiomyocyte proliferation and activation of endogenous cardioblasts come into play (on a time scale of weeks). Many animal studies have investigated cells in nonreperfused AMI, 32 and several others have targeted chronically scarred myocardium. [33] [34] [35] [36] Surprisingly little is known about the utility and risks of intracoronary cell administration soon after (ie, within 20-45 minutes of) reperfusion. No clinical data are available; cell therapy clinical trials have generally infused cells 1 to 14 days post-AMI. 37 By that time, cardiomyocytes at risk are already dead, so there is limited potential (if any) for myocardial salvage. [38] [39] [40] Given the delays intrinsic to autologous tissue harvesting and cell processing, applications in the acute reperfusion phase will require allogeneic (off-the-shelf donor-derived) products. Preclinical studies of acutely administered allogeneic mesenchymal stem cells [41] [42] [43] or their precursors 44 have yielded variable results. Some studies have questioned the safety of intracoronary infusion of cells post-MI, with decreased coronary flow and elevation of cardiac enzymes attributed to microvascular plugging. [41] [42] [43] 45 Houtgraaf et al 44 had more favorable results with mesenchymal precursor cells after careful attention to cell dosage and infusion rate. These investigators began infusion at 15 minutes of reflow, and they quantified infarct size only at 8 weeks, at which time longer-term regenerative effects may cloud the evaluation of cardioprotection. 46 Table 3 lists all cell types that have been tested in animal models of AMI, along with the following information for each cell type: the most advanced preclinical model tested; the immune match tested (syngeneic, allogeneic, and xenogeneic); whether or not cardioprotection has been demonstrated histologically in 48-to 72-hour follow-up after postreperfusion cell delivery; and clinical testing status (any clinical testing, and clinical testing specifically in AMI adjunctive to reperfusion). The only cell types to have been shown to be cardioprotective are cardiosphere-derived cells, which are discussed further below.
CARDIOSPHERE-DERIVED CELLS
Over the past 12 years, cardiosphere-derived cells (CDCs) have emerged as a candidate cell type for regenerative therapy post-MI. 64 Unlike many other cell therapy products, the mechanism of action of CDCs is well understood. These heart-derived cells exhibit multilineage potential and clonogenicity, 64 but they work primarily through indirect mechanisms. 60 At least 35 independent laboratories worldwide have generated CDCs and verified their therapeutic bioactivity. CDCs were first tested clinically in the CADUCEUS trial (Cardiosphere-Derived Autologous Stem Cells to Reverse Ventricular Dysfunction), 65, 66 which examined the safety and efficacy of intracoronary autologous CDCs in 17 patients with LV dysfunction and convalescent MI (1.5-3 months prior), in comparison with 8 randomly assigned controls. The results were promising in revealing evidence of therapeutic regeneration with CDCs, but the chronicity of the MI ruled out any contribution from cardioprotection in that study. Although heart-derived stem cells have been tested in both large animals and humans in chronic ischemic settings, 36, 66 until recently, the only studies using an acute ischemia/reperfusion (I/R) model were in rats, 65, 67 where structural and functional outcomes were improved dramatically by the intracoronary infusion of allogeneic CDCs 20 minutes post-AMI. However, the 3-week end point in those studies made it impossible to separate cardioprotection from regeneration.
INDIRECT EFFECTS OF CDCS
In the vast majority of experimental studies, the number of differentiated myocytes derived from transplanted stem cells is too small to account for the observed improvements in cardiac function. 60 Thus, the prevailing concept of stem cell efficacy has shifted toward the paracrine hypothesis, which proposes that transplanted cells produce soluble factors beneficial to the infarcted heart. 68 Potential cardioprotective effects of paracrine factors include antiapoptotic effects on resident myocytes, 67 ,69 upregulation of angiogenesis, 60, 70 modulation of inflammatory processes resulting in better infarct healing, 71 promotion of cardiomyocyte cell cycle reentry, 31 and induction of secondary humoral effects in the host tissue. 72, 73 Recent findings implicate exosomes as critical agents of the indirect effects of CDCs, likely attributable, at least in part, to the transfer of cardioprotective and regenerative microRNAs (eg, miR-146a) from CDCs to surrounding heart tissue.
74

ROLE OF INFLAMMATION AND MACROPHAGES
Innate immunity pathways are recruited to deal with sterile inflammation, as occurs in AMI. The first step is an intense influx of neutrophils within minutes of injury. Macrophages (Mϕ) are then mobilized to clear necrotic debris, antagonize further neutrophil entry, and begin wound healing. [75] [76] [77] Although there is ample evidence that neutrophils exacerbate I/R injury by killing damaged (but salvageable) cardiomyocytes, 78 nonselective inhibition of inflammation has not proven to be useful therapeutically. [79] [80] [81] [82] Targeting of distinct immune cell populations and subpopulations may be a more viable strategy. Mϕ, in particular, are an important potential target; they can originate within the heart (tissue-resident Mϕ) or from a blood-borne influx of monocytes, which then differentiate into Mϕ in the tissue. 83 Despite the common classification of Mϕ into either M 1 or M 2 subpopulations (with proinflammatory or reparative properties, respectively), Mϕ are highly plastic and can assume a variety of activated states in response to microenvironmental cues. 83, 84 In fact, at least 4 distinct resident Mϕ subsets exist within the adult heart under normal conditions. 85 Following AMI, both resident and monocyte-derived Mϕ expand their populations to regulate repair with several distinct phenotypes, modulating phagocytosis, antigen presentation, and T-cell acti- vation. 85, 86 It is interesting to note that in the neonatal heart, Mϕ are essential for cardiac regeneration, a function lost within days of birth.
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CELLULAR POSTCONDITIONING
In 2014, the laboratory of one of the authors (E.M.) demonstrated the phenomenon of cellular postconditioning: CDCs are cardioprotective when given within a reasonable delay after I/R in AMI. In pigs subjected to 90 minutes of ischemia and 30 minutes of reflow, the intracoronary infusion of CDCs decreased infarct size and also reduced the extent of microvascular occlusion measured at 48 hours. 88 Cyclic sham interruptions of coronary flow starting 30 minutes post-I/R were not cardioprotective, distinguishing CDC-related cardioprotection from ischemic postconditioning. To be absolutely certain that ischemic postconditioning did not confound the results, we performed a new set of experiments using nonocclusive continuous-flow methods to deliver CDCs into the infarct-related artery 30 minutes after reflow in AMI pigs. Figure 1 confirms robust infarct size reduction measured histologically, and preservation of LV ejection fraction, wall thickness, and wall motion using MRI, as well. These new data provide additional evidence of the protective effects of CDC postconditioning. After the initial report in pigs, we published a follow-on mechanistic study in rats with AMI. 89 This work confirmed and extended the initial findings: intracoronary infusion of CDCs at 20 minutes of reperfusion reduced infarct size and improved functional recovery. CDCs decreased the number of myocardial CD68 + Mϕ, and these CDCs secreted factors that polarized Mϕ toward a distinctive cardioprotective phenotype. Systemic depletion of Mϕ with clodronate abolished CDC-mediated cardioprotection. Post-I/R adoptive transfer of CDC-conditioned Mϕ also reduced infarct size, recapitulating cellular postconditioning. Thus, CDCs appear to limit acute injury by polarizing an effector Mϕ population within the heart.
Given the concerns articulated earlier, any putative new cardioprotective mechanism will understandably be greeted skeptically. Thus, independent validation of the basic phenomena is highly desirable. Using blinded analysis and randomization, the Lefer laboratory (one of the principals in the CAESAR network, and an author here) has now independently reproduced the findings of robust cardioprotection by CDCs. Figure 2 shows the results of a study in which allogeneic rat CDCs were administered 20 minutes following reperfusion in the spontaneously hypertensive rat AMI model. Placebo (phosphate-buffered saline)-injected spontaneously hypertensive rats exhibit very large areas of infarction (ie, >50% of the area-atrisk) following coronary I/R. CDC postconditioning significantly attenuated myocardial infarct size and plasma cardiac troponin I levels at 48 hours postreperfusion. It its interesting to note that LV structure and function were preserved in CDC-treated spontaneously hypertensive rats at 28 days post-AMI in comparison with rats that had received phosphate-buffered saline (Figure 2 ), verifying that the effects are durable (as the Marbán laboratory had shown in another pig study). Extensive evidence supports the notion that extracellular nanovesicles called exosomes are secreted by CDCs and mediate their salient effects, likely via cell-cell transfer of noncoding RNAs, including microRNAs (although exosomes contain a redundancy of other bioactive molecules, including proteins and transcripts). 91 The effects of CDCs on macrophages are replicated by CDC-secreted exosomes (CDC exo ), and CDC exo them- selves mimic cellular postconditioning. 92 Although the cascade of microRNA transfer and target gene suppression might seem too slow to mediate a process that necessarily must be rapid to prevent substantial cardiomyocyte death, microRNAs are known to be capable of suppressing proinflammatory gene expression in just 1 hour. 93 A host of acute and longer-term salutary effects ensue. Within just 2 hours, cardiomyocyte apoptosis in the postischemic heart is inhibited by ≈60%. 89 Meanwhile, macrophages are altered so as to become cytoprotective. CDC exo -polarized macrophages exhibit enhanced phagocytosis; our working hypothesis posits that such macrophages become more efficient in clearing necrotic debris (thereby enhancing the healing process known as efferocytosis). 94, 95 The net effects are a reduction of infarct size evident early, with sustained structural and functional benefits. The recognition of a central mechanistic role for CDC exo begs the question of whether cell-free therapeutics may be able to recruit benefits equivalent to cellular postconditioning. In the long run, this possibility seems likely: as we come to recognize the key bioactive components within CDC exo , they may become effective therapeutic agents on their own, either naked or packaged within designer exosomes. In the immediate future, however, CDC exo themselves may not be a realistic, alternative therapeutic candidate to CDCs. Although CDC exo reproduce the salient benefits of CDCs, we have recently reported, in a porcine model of cellular postconditioning, that intramyocardial injection is required for efficacy. 96 The intracoronary route is far preferable clinically, especially in the set- Cardiosphere-derived cells (CDCs) release exosomes resulting in the transfer of RNA and proteins to macrophages, fibroblasts, endothelial cells, and cardiomyocytes, in turn, leading to both acute and late cardioprotective actions. In the acute phase of reperfusion injury, CDCs improve cardiomyocyte viability and reduce myocardial infarct size by the conversion of resident macrophages to a cardioprotective phenotype and dampening the innate immune response. During the later phases of myocardial reperfusion injury, CDC therapy results in sustained infarct size reduction by alterations in polarization of infiltrating macrophages, accelerated clearance of necrotic debris, and significant attenuation of the late inflammatory response in the myocardium.
ting of recent reperfusion when the heart can be particularly susceptible to ventricular arrhythmias. 97 Thus, CDCs, which are effective after intracoronary delivery (Figures 1 and 2 , and references [55] [56] [57] ), continue to be the prime therapeutic candidate for reducing infarct size translationally, as discussed further below.
NEW CONCEPTS SUGGEST NEW APPROACHES
The discovery that CDCs work in AMI despite being administered with some delay after reperfusion is notable, because it avoids the need for pretreatment and immediate intervention on reopening the affected artery. 98 The concept of cellular postconditioning is novel, and merits comparison with other cardioprotective processes that can be recruited pharmacologically and by transient ischemia (preconditioning and ischemic postconditioning). Unlike those phenomena, however, cellular postconditioning has the unique advantage of being recruitable 30 minutes after reperfusion (and perhaps even longer; the precise limits of the cardioprotective window remain to be defined). The idea that cell therapy may mitigate ischemic injury by modulating Mϕ is supported by recent work, 89 and is consistent with the immunomodulatory properties described for CDCs. 99, 100 Although inflammation figures prominently in AMI, there has been little by way of targeted intervention to take advantage of our exploding knowledge of innate immunity pathways and Mϕ biology. Although not originally conceived as selectively targeting inflammation to reduce infarct size, CDCs may turn out to achieve this long-elusive goal.
PROSPECTS FOR TRANSLATION
Few of the cell types tested preclinically in AMI model have progressed to clinical testing ( Table 3) . As summarized in Table 4 , allogeneic CDCs are already in advanced clinical testing; they have proven safe to date in >100 patients treated by coronary infusion.
Thus, from a product readiness viewpoint, it should be straightforward to initiate clinical testing of the hypothesis that CDCs induce cellular postconditioning, targeting end points including infarct size and LV ejection fraction. Demonstration of efficacy in humans would comprise the ultimate proof of concept that cellular postconditioning is genuine. Nevertheless, some cautionary notes are worth considering before launching into clinical trials. First, dosing of the CDCs needs to be carefully adjusted. CDCs are large cells that can be microcclusive. 34 In the setting of AMI, where microvascular occlusion already can occur, intermediate dosing may be required: too few infused cells will be ineffective, while too many may actually worsen preexisting microvascular occlusion. Even in the highly controlled pig model, we have found that excessively high doses result in decreased efficacy, consistent with the Goldilocks caveat. In humans with highly variable degrees of I/R injury on presentation with AMI, it will be even more challenging to estimate a safe-but-effective dose. A second consideration is the fact that it is exceedingly difficult, in the AMI setting, to determine which patients will go on to develop large infarcts. The results of early percutaneous intervention are so overwhelmingly positive, even for patients presenting with hypotension and tombstone Ts, that entry criteria are now difficult to establish reliably for any cardioprotective protocol. On balance, proceeding with relatively low CDC doses and broad inclusion criteria seems most prudent, recognizing that the number of patients one must treat to see benefit will necessarily be increased by such a conservative approach. The ongoing AMICI trial (Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction) of allogeneic mesenchymal precursor cells in AMI may provide helpful safety data and insights into dosage to help guide future trials (Clinicaltrials.gov NCT01781390). Indeed, mesenchymal precursor cells are the first cells to be tested clinically as adjunctive therapy to percutaneous intervention in AMI (Table 3) .
CONCLUSIONS
Despite >40 years of effort and thousands of reports of therapies claiming to limit myocardial infarct size in the setting of AMI, there are no approved treatments to supplement the unambiguous efficacy of early reflow.
Recent data reviewed here demonstrate the powerful effects of cellular postconditioning with CDCs administered following reperfusion. Here we additionally provide compelling unpublished data from 2 different laboratories in 2 different animal species demonstrating robust cardioprotection when CDCs are administered 20 to 30 minutes following reperfusion. These studies demonstrate major reductions in myocardial infarct size in the spontaneously hypertensive rat and in the Yucatan miniswine model. Reductions in infarct size are accompanied by improved LV function and preservation of myocardial blood flow with attenuated no-reflow. Cellular postconditioning may be clinically tractable, providing new hope that myocardial reperfusion injury can be effectively targeted. The jury is still out, but we conclude that cardioprotection against AMI is not dead…at least, not yet.
